A Bovine Model of Respiratory Chlamydia psittaci Infection: Challenge Dose Titration by Reinhold, Petra et al.
A Bovine Model of Respiratory Chlamydia psittaci
Infection: Challenge Dose Titration
Petra Reinhold
1*, Carola Ostermann
1, Elisabeth Liebler-Tenorio
1, Angela Berndt
1, Anette Vogel
1,
Jacqueline Lambertz
1, Michael Rothe
3, Anke Ru ¨ttger
1, Evelyn Schubert
1,2, Konrad Sachse
1,2
1Institute of Molecular Pathogenesis at ‘Friedrich-Loeffler-Institut’ (Federal Research Institute for Animal Health), Jena, Germany, 2OIE Reference Laboratory for
Chlamydiosis at ‘Friedrich-Loeffler-Institut’ (Federal Research Institute for Animal Health), Jena, Germany, 3LIPIDOMIX GmbH, Berlin, Germany
Abstract
This study aimed to establish and evaluate a bovine respiratory model of experimentally induced acute C. psittaci infection.
Calves are natural hosts and pathogenesis may resemble the situation in humans. Intrabronchial inoculation of C. psittaci
strain DC15 was performed in calves aged 2–3 months via bronchoscope at four different challenge doses from 10
6 to 10
9
inclusion-forming units (ifu) per animal. Control groups received either UV-inactivated C. psittaci or cell culture medium.
While 10
6 ifu/calf resulted in a mild respiratory infection only, the doses of 10
7 and 10
8 induced fever, tachypnea, dry cough,
and tachycardia that became apparent 2–3 days post inoculation (dpi) and lasted for about one week. In calves exposed to
10
9 ifu C. psittaci, the respiratory disease was accompanied by severe systemic illness (apathy, tremor, markedly reduced
appetite). At the time point of most pronounced clinical signs (3 dpi) the extent of lung lesions was below 10% of
pulmonary tissue in calves inoculated with 10
6 and 10
7 ifu, about 15% in calves inoculated with 10
8 and more than 30% in
calves inoculated with 10
9 ifu C. psittaci. Beside clinical signs and pathologic lesions, the bacterial load of lung tissue and
markers of pulmonary inflammation (i.e., cell counts, concentration of proteins and eicosanoids in broncho-alveolar lavage
fluid) were positively associated with ifu of viable C. psittaci. While any effect of endotoxin has been ruled out, all effects
could be attributed to infection by the replicating bacteria. In conclusion, the calf represents a suitable model of respiratory
chlamydial infection. Dose titration revealed that both clinically latent and clinically manifest infection can be reproduced
experimentally by either 10
6 or 10
8 ifu/calf of C. psittaci DC15 while doses above 10
8 ifu C. psittaci cannot be recommended
for further studies for ethical reasons. This defined model of different clinical expressions of chlamydial infection allows
studying host-pathogen interactions.
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Introduction
The obligate intracellular bacterium Chlamydia (C.) psittaci is the
causative agent of psittacosis, a widespread infection in psittacine
birds and domestic poultry [1–3]. Transmission of C. psittaci to
humans and the zoonotic potential of this infection were first
documented in the 19th century. Outbreaks of human C. psittaci
infections still occur [4,5], but the number of reported cases today
is thought to be underestimated due to inadequate epidemiological
coverage and insufficient diagnostic testing [6,7]. During the last
decade, C. psittaci has also been regularly detected in non-avian
domestic animals, i.e. swine, horses, dogs, cattle, and sheep [8–13].
Although serological data from the 1990s already indicated
chlamydioses in domestic animals as a relevant source of infection
for humans [14], C. psittaci strains of non-avian origin have not
been in the focus of extensive research. Both their pathogenic role
in large animals and their zoonotic potential to humans have
remained elusive to date.
In natural hosts, clinical outcomes of C. psittaci infection range
from clinical silence to severe or even life-threatening illness,
suggesting that host-pathogen interactions are important to the
pathogenesis. Psittacosis in birds is known as a systemic disease of
acute, protracted, chronic or subclinical course. Psittacosis in
humans is recognized mainly as a respiratory infection initially
reminiscent of an influenza-like illness and atypical pneumonia,
but may also manifest as a fulminant course including myocar-
ditis, hepatitis, and encephalitis [15–17]. Diversity of chlamydial
infection expression in calves ranges from acute respiratory illness,
keratoconjunctivitis or polyarthritis [18–20] to clinically inappar-
ent infections in the majority of herds [13]. Despite clinical silence,
chlamydial infections in young cattle were found to be associated
with long-lasting respiratory dysfunctions [21] indicating patho-
genetic involvement of the respiratory system in ‘‘asymptomatic’’
bovine chlamydiosis.
Relevant animal models of chlamydial infections are needed to
answer open questions about (i) the pathogenetic role of non-avian
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outcomes, and (ii) transmission routes of this potentially zoonotic
agent between different hosts. As calves represent natural hosts for
chlamydiae [20,22,23] they offer the possibility to analyze host-
pathogen interactions under natural conditions. In contrast,
artificial murine models imperfectly recapitulate many aspects of
infectious diseases due to host restriction in non-typical hosts [24].
Furthermore, the following peculiarities in genetics, immunobiol-
ogy and respiratory physiology reveal species-specific aspects that
suggest large-animal models becoming an obligatory complement
to widely used murine models.
Genetics
The bovine genome, fully sequenced in 2009, more closely
resembles the human genome than that of mice and rats [25].
Comparative analyses further revealed that sequences of bovine
proteins are generally more similar to human orthologs than are
rodent orthologs [26]. In general, recent data about genome
diversity confirmed that the mouse genome is much more
rearranged than that of most other taxa [27].
Immunobiology
With respect to the genetically determined regulation of defense
mechanisms, significant differences exist between species (reviewed
by [28]). For example, interleukin-8 (IL-8) plays a significant role
in human inflammatory processes. In the mouse genome, the il-8
gene is missing; but it does exist in the genome of dogs, pigs, sheep,
and cattle. The protein encoded in cattle even exhibits a high
cross-species activity with human IL-8 [29,30]. Further significant
differences between murine and human innate and adaptive
immune response are related to such important aspects as the Toll
receptors, inducible NO synthase, Fc-Receptors, immune globulin
subsets or immune mediators (summarized by [31,32]). Particu-
larly for chlamydial infections, marked host-adapted differences in
the IFN-gamma response have been recently discovered compar-
ing mice and humans [24].
Respiratory Physiology
Considering the murine lung as a model for human respiratory
diseases, one has to be aware of numerous structural and
functional peculiarities (summarized by [33,34]). The most
important differences include the branching pattern of the bronchi
(monopoidal pattern in mice versus dichotomous pattern in larger
mammalian lungs) and the lack of bronchial vessels in mice. Due
to the latter, several steps of leukocyte infiltration in the bronchial
wall will be completely different compared to larger mammalian
lungs. Furthermore, Clara cells are present in about 50% of
airways in mice but are rare in conducting airways of humans and
other larger species where goblet (mucus) cells dominate. This
difference significantly influences production of mucus and con-
sequently the function of mucociliary clearance as an important
defense mechanism to eliminate inhaled particulate antigens.
That mice do not faithfully reproduce pathophysiological
aspects of human pulmonary disease (due to many significant
differences in lung anatomy, respiratory physiology, and pulmo-
nary immunology) has been shown for airway epithelium repair
and regeneration, asthma, cystic fibrosis, various cancers, and
various pulmonary infections - for example tuberculosis or MRSA
[35–43]. In contrast, lung volumes, airflows and respiratory
mechanics are comparable between adult humans and calves due
to comparable body weights (50–100 kg), and the bovine lung is
particularly suited to mirror pulmonary dsyfunctions [39].
The current study was undertaken to establish and evaluate a
bovine respiratory model of experimentally induced C. psittaci
infection because calves are likely to resemble more closely than
mice the situation in humans and also because chlamydial
infections play an important role in cattle. As data on dose-
response-relationships of chlamydial infections in the bovine
respiratory system were absent, dose titration of the inoculum
was the main goal of this study. Clinical outcomes, markers of
pulmonary inflammation, lung pathology, recovery of chlamydiae
and humoral response were assessed after intrabronchial challenge
of doses between 10
6–10
9 inclusion forming units (ifu) per animal.
Results of this study reveal that both clinically latent and clinically
manifest C. psittaci infection can be reproduced experimentally.
This defined model of a predictable severity of illness is essential
for further research to understand the underlying pathogenetic
mechanisms of different clinical phenotypes of chlamydial
infection, and to clarify details about dissemination, shedding
and transmission of C. psittaci as it relates to the clinical picture.
Results
1. Clinical signs
Control calves challenged with either cell culture medium
(n=4) or the inactivated C. psittaci strain (n=6) did not exhibit any
clinical sign of respiratory illness (Fig. 1A). In calves exposed to
viable C. psittaci, the total clinical score increased with increasing
doses of inoculum (Fig. 1B). Clinical illness manifested as
respiratory signs and was confirmed by the respiratory score that
contributed to about 50% to the general clinical score (data not
shown). Clinical illness was most evident 2–3 days post inoculation
(dpi). As examples, body temperatures and respiratory rates
measured at the peak of clinical signs (i.e. 48–72 hours pi) are
shown in Figure 2. Beside fever and respiratory illness, the
following dose-dependent clinical signs were evident:
N In calves challenged with 10
6 ifu (n=4), mild diarrhea and
spontaneous cough occurred without apparent affect on
appetite, feed intake or general behavior. Nasal or ocular
discharge was not observed.
N Calves exposed to 10
7 ifu (n=4) or 10
8 ifu (n=4) developed
clinical illness of similar severity characterized by fever
(Fig. 2A), tachypnea (Fig. 2B) and mild tachycardia (medians
[ranges] of heart rates: 90 [68–120] beats min
21 for 10
7 ifu/
calf; 82 [72–108] beats min
21 for 10
8 ifu/calf). In most of
these calves, appetite and milk intake was reduced at 2–3 dpi,
and diarrhea was seen in a few animals. In all calves, dry cough
occurred while nasal and ocular discharges were rarely seen. In
general, the period of 2–3 dpi was accompanied by reduced
general activity (dullness).
N The most severe clinical picture was present in two calves
challenged with 10
9 ifu. Within the period 2–3 dpi, general
behavior was mostly depressed and accompanied for 6–
12 hours by apathy, inability to stand up, tremor, markedly
reduced appetite or complete feed rejection with or without
diarrhea. Heart rate increased to approximately 160%
compared to baseline data (median [range]: 106 [88–124]
beats min
21). Dry cough was present while nasal and ocular
discharges were rarely seen. Due to severity of clinical illness,
the two calves were euthanized 3 dpi and no further calves
were exposed to 10
9 ifu.
In the three groups challenged with 10
6,1 0
7,o r1 0
8 ifu of C.
psittaci, clinical signs returned to baseline within one week after
challenge (data not shown).
Respiratory C. psittaci Infection Model
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Results of BALF cytology obtained during the acute phase, i.e.
2–3 dpi, are summarized in Table 2. Total cell count in BALF was
higher in calves challenged with viable chlamydiae compared to
controls, and counts increased with challenge dose. Although
absolute numbers of all cell types (i.e. alveolar macrophages,
granulocytes, and lymphocytes) contributed to elevated total cell
counts in calves challenged with viable chlamydiae, the most
significant increase was attributed to neutrophil granulocytes,
particularly unsegmented ones. Percentages of the three cell types
revealed that the relative amount of alveolar macrophages
decreased significantly in a dose-dependent manner because the
percentage of mainly unsegmented neutrophil granulocytes
increased.
BALF cytology of the calves that had been exposed to viable C.
psittaci and necropsied at 7 dpi still showed dose-dependent effects.
For example, total cell counts 7 days after exposure to 10
6,1 0
7,
and 10
8 ifu were still 4.8, 7.0, and 8.2610
8/L, respectively. In
calves sacrificed at 14 dpi, BALF cytology did not differ from those
of control calves (data not shown).
The concentration of total protein in BALF supernatant was
,300 mg/mL in controls as well as in groups challenged with 10
6
or 10
7 ifu. Protein concentration in BALF increased in the group
challenged with 10
8 ifu, and was dramatically elevated after
inoculation of 10
9 ifu of C. psittaci (Fig. 3A).
As shown in Figure 3B as a typical example, eicosanoids, i.e.
thromboxan B2 (TXB2), prostaglandin E2 (PGE2), and hydro-
xyeicosatetraenoic acids (15-HETE, 12-HETE), were almost
undetectable in BALF supernatants of the control animals but
became measurable in calves challenged with doses above 10
6 ifu
and attained highest concentrations in BALF samples of calves
exposed to 10
9 ifu.
Figure 1. Development of the total clinical score over time. Data are given as regression lines and individual data according to the best fitting
regression model per group. In control calves, no significant changes of total clinical score occurred after inoculation of medium or inactivated
chlamydiae (panel A). In calves experimentally inoculated with different doses of viable C. psittaci, scores of clinical illness increased with challenge
doses (panel B). Equations of regression, coefficients of correlation, R-squared values, and probability levels are given in Table 1.
doi:10.1371/journal.pone.0030125.g001
Figure 2. Rectal temperature and respiratory rate measured
48–72 hours post inoculation (i.e. peak of clinical signs). In
calves experimentally inoculated with different doses of viable C.
psittaci, both rectal temperature (panel A) and respiratory rate (panel B)
were significantly increased while no significant changes were seen in
control calves. Data are given as Box-and Whisker Plots based on 2 or 3
measurements per calf in controls or infected animals, respectively.
Different letters indicate significant differences between groups at
given P-level (multiple range test).
doi:10.1371/journal.pone.0030125.g002
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3.1. Gross lesions. Bronchopneumonia was seen in all calves
exposed to viable C. psittaci, but in none of the calves inoculated
with cell culture medium or inactivated C. psittaci. Distribution of
lesions was consistent with the sites where inoculum had been
applied. Thus, the most extensive involvement was seen in the
middle lobe and in the left and right basal lobes (Fig. 4). Especially
in the basal lobes, lesions were often not readily visible at the
surface, but located deep within the tissue (Fig. 4). At the time
point of most pronounced clinical signs, i.e. 3 dpi, the extent of
lesions was below 10% of pulmonary tissue in calves inoculated
with 10
6 and 10
7 ifu C. psittaci. The proportion increased to about
15% in calves inoculated with 10
8 and to more than 30% in calves
inoculated with 10
9 ifu C. psittaci.
In calves inoculated with 10
6,1 0
7 and 10
8 ifu C. psittaci
necropsied at 7 dpi, lesions were still present in the basal lobes, but
at 14 dpi lesions had almost resolved.
3.2. Histological lesions and detection of chlamydial
inclusions by immunohistochemistry. Neither histological
lesions nor chlamydial inclusions were seen in the calves ino-
culated with medium or with inactivated chlamydiae. In the calves
challenged with viable chlamydiae, the presence of C. psittaci
inclusions was mainly restricted to altered pulmonary tissue, and
macroscopic lesions were confirmed by histology as follows:
At 3 dpi, purulent bronchopneumonia was seen predominantly
in calves inoculated with 10
6 and 10
7 ifu C. psittaci. Small foci with
fibrinous exsudate and necrosis were seen only in severely affected
lobes. The number of chlamydial inclusions was low, and had a
multifocal distribution. Chlamydial inclusions were seen in
alveolar epithelial cells. After inoculation of 10
8 ifu C. psittaci,
fibrinopurulent bronchopneumonia with multifocal areas of
necrosis and pleuritis was frequently observed. The number of
chlamydial inclusions was further elevated and the inclusions were
often associated with neutrophils and macrophages. In calves
inoculated with 10
9 ifu C. psittaci, areas of necrosis were more
extensive and numerous chlamydial inclusions were found
throughout the altered tissues.
At 7 dpi, an increased number of alveolar macrophages and
mild lymphohistiocytic infiltrates occurred, indicating organization
of pneumonic lung tissues. Extensive areas of necrosis were seen in
the calf inoculated with 10
8 ifu C. psittaci, multifocal areas in the
calf inoculated with 10
7 ifu C. psittaci and none in the calf
inoculated with 10
6 ifu C. psittaci. Chlamydial inclusions were
numerous in areas of necrosis, but infrequent in those of
organization.
At 14 dpi, lesions had resolved in the calf inoculated with
10
6 ifu C. psittaci. The lung of the calf that had received 10
7 ifu
C. psittaci had multiple areas with thickened interalveolar
septae, alveolar epithelial cell type II hyperplasia and lymphocytic
infiltrates. Few chlamydial inclusions were found overall, but there
were a few foci with groups of macrophages containing chlamydial
inclusions.
4. Quantification of chlamydial antigen in the lung
Examination of lung tissue by real-time PCR revealed that
genome copy numbers of C. psittaci in lung tissue at 3 dpi increased
with the challenge dose (Figure 5). Seven days after challenge,
copy numbers of the pathogen were still dose-dependent but
already significantly reduced compared to 3 dpi. Fourteen days
post inoculation, less than 30 copies/mg were detectable in lung
tissues of calves challenged with viable chlamydiae.
In lung lymph nodes, similar dose-dependent effects were seen
at 3 dpi, but absolute copy numbers per mg of lymph node tissue
were much lower compared to those found in lung tissue (data not
shown). In cell pellets of BALF, highest copy numbers were seen at
3 dpi in the two calves challenged with the highest dose of 10
9 ifu/
calf (621 and 1611 copies per 10
4 BALF-cells), while hardly any C.
psittaci were found in BALF cells of the other groups at any time
point.
5. Humoral response
Specific antibodies against the challenge pathogen were
detected mainly in the group of animals exposed to 10
8 ifu C.
psittaci, where reactive bands were detected in serum on day 7 after
inoculation (Fig. S1). Sera from the groups infected with 10
7 and
10
6 ifu failed to show a specific immune reaction in the first 11
days after challenge. Immunoblot analysis of BALF supernatants
showed only a weak reaction for the group exposed to 10
8 ifu on
7 dpi (Fig. S1). Since the two calves challenged with 10
9 ifu had
been sacrificed already at 3 dpi, no data of their specific humoral
response is available.
Discussion
1. Model validity
To the best of our knowledge, this is the first study assessing
dose response effects to the pathogen C. psittaci in a domestic
animal model of respiratory infection. Despite the known
disadvantages in terms of cost, time consumption and limited
availability of immunological and molecular tools compared to
widely used murine models, calves were selected because (1)
bovine chlamydiosis closely resembles the situation in a natural
host [21,23], (2) the C. psittaci isolate (strain DC 15) used to
establish the model originated from a calf, and (3) the bovine lung
is more relevant than the mouse to model human functional
consequences of ventilatory disorders due to its segmental anatomy
and the lack of collateral airways [39]. Furthermore, domestic
animal models are especially advantageous because they can be
Table 1. Assessment of regression lines of the clinical scores given in Figure 1.
Challenge Best fitting regression model
Coefficient
of correlation R-squared
medium linear [Y=a+b*X] 20.13 1.57% P.0.10
Cp inactivated square root-X model [Y=a+b*sqrt(X)] 0.20 4.08% P.0.10
10
6 ifu/calf square root-X model [Y=a+b*sqrt(X)] 0.78 61.62% P,0.001
10
7 ifu/calf Linear model [Y=a+b*X] 0.91 83.36% P,0.001
10
8 ifu/calf Linear model [Y=a+b*X] 0.96 91.40% P,0.001
10
9 ifu/calf square root-X model [Y=a+b*sqrt(X)] 0.88 77.54% P,0.001
doi:10.1371/journal.pone.0030125.t001
Respiratory C. psittaci Infection Model
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biomedical research [44,45]. From an epidemiological point of
view, infectious diseases in farm animals are useful biological
models to provide empirical data that aids infectious disease
modeling and to advance our understanding of infectious disease
dynamics and control for human populations [46].
Due to ethical criteria of animal protection, calves included
were limited to the lowest number essential to document inherent
differences in host responses (4 calves per challenge dose 10
6–
10
8 ifu/calf; 2 calves per challenge dose 10
9 ifu/calf). This small
animal number was sufficient because large animals offer the great
advantage of enabling the characterization of functional, inflam-
matory and morphological changes in a multi-factorial within-
subject approach.
With respect to the pathogen, previous models of respiratory ‘C.
psittaci infection’ in domestic animals published more than 20 years
ago have to be critically scrutinized on the basis of current tax-
onomy. For instance, isolates of C. psittaci from ovine pneumonia
were inoculated either endobronchially in red deer [47] or
intratracheally in pigs [48] to produce pneumonia. Experimentally
induced pneumonia by intratracheal inoculation of different
strains of the old Chlamydia psittaci sensu lato (now comprising the
species of C. abortus, C. felis, C. caviae and C. psittaci) was also
reported for pigs and calves [49–51]. From today’s perspective, in
the light of two recent revisions of the taxonomy of Chlamydiales
[52,53], it is doubtful that those models actually used the species
currently defined as C. psittaci.
2. Dose-dependent effects of C. psittaci in the host
Clinical signs of illness increased with challenge doses in all
calves exposed to viable C. psittaci. While 10
6 ifu/calf resulted in
mild clinical signs only, the doses of 10
7 and 10
8 induced clinically
apparent illness that became visible 2–3 dpi. Comparing the latter
two doses, the clinical picture induced by 10
8 ifu was more
reproducible. Doses above 10
8 ifu C. psittaci cannot be recom-
mended for further studies for ethical reasons.
According to BALF cytology, increasing numbers of cell types
capable of phagocytosis and antigen presentation were recruited
with increasing challenge doses of C. psittaci. The early recruitment
of neutrophils is in line with results obtained after aerogeneous C.
suis infection in pigs [54] and in a murine model of Chlamydia
infection [55]. In our model, predominantly juvenile unsegmented
neutrophils were recruited as the first line of defense in a dose-
dependent manner. To a smaller extent, alveolar macrophages
and lymphocytes also contributed to the increase of cells in
broncho-alveolar compartments.
Concentrations of total protein in BALF indicated severity of
inflammation and increased permeability of pulmonary vessels for
challenge doses above 10
7 ifu/calf. Increases in protein concen-
tration .600 mg/mL BALF as seen after inoculation of 10
8 ifu of
C. psittaci are in accordance with data published for calves with
naturally acquired chlamydial infections [21]. Dramatically
elevated protein concentrations in BALF samples of the two
calves exposed to 10
9 ifu of C. psittaci demonstrated dramatic loss
of integrity of the alveolo-capillary barrier in the lung, which is line
with the particularly severe clinical outcome.
The pathogenetic link between chlamydial infection and
activation of the arachidonic acid (AA) cascade via the cycloox-
ygenase (COX)-mediated pathway has been shown in vitro for
multiple cell types such as epithelial cells, peripheral blood
mononuclear cells, human monocytes, and antigen-presenting
Figure 3. Markers of pulmonary inflammation assessed in
broncho-alveolar lavage fluid (BALF). Both concentration of total
protein (A) and 12-HETE (B) were maximal in calves inoculated with
10
9 ifu of C. psittaci. Data for control groups are from 2 and 3 dpi
combined (Box and Whisker Plots). Data for calves challenged with
different doses of viable C. psittaci are given on an individual basis for
time points when calves were sacrificed (filled circles: 3 dpi; open
circles: 7 dpi and 14 dpi). Kruskal-Wallis test revealed significant
differences between groups at given P-level.
doi:10.1371/journal.pone.0030125.g003
Figure 4. Distribution and extent of pulmonary lesions at day
3 pi in a calf inoculated with 10
9 ifu of C. psittaci. Dorsal view of
the lung and heart (H). Pneumonic lesions present as dark red
discolorations (.) in the apical lobes, middle lobe and basal lobes.
Note distension of the basal lobes due to severe bronchopneumonia in
the inferior segments (hatched lines). Bar=5 cm.
doi:10.1371/journal.pone.0030125.g004
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pathway were increasingly obvious with increasing challenge doses
indicating that the AA cascade became more intensively involved
in pulmonary host response as the chlamydial inoculum increased.
This finding is in good agreement with in vitro data obtained in
human monocytes showing that the amount of synthesized
eicosanoids was dependent on the chlamydial multiplicity of
infection [60]. While in vitro studies focused mainly on PGE2, in
vivo data of our study revealed that concentrations of at least four
eicosanoids (TXB2, 15-HETE, 12-HETE, and PGE2) increased
with chlamydial load in lung tissue.
Differences in the quantity of pulmonary tissue affected by
pneumonia were well correlated with the severity of clinical signs.
A dose-dependent increase in the number of pulmonary lesions
and in the type of lesions was observed. There was a continuous
change from purulent to fibrino-exsudative lesions and in the
extent of necrosis. Similar changes may be seen after deposition of
foreign material in the lung causing aspiration pneumonia.
However, since lesions occurred after inoculation with viable
chlamydiae only, they are most likely a consequence of the
replicating bacteria. Early organization of pulmonary lesions
was seen at 7 dpi. Chlamydiae were still present in areas of
inflammation, but had been cleared from areas of organization. At
14 dpi, reconstitution was complete in calves that had received
10
6 ifu of C. psittaci. In calves that had received the higher doses,
areas of necrosis had not yet been completely organized and
chlamydiae could still be found in these areas.
Specific antibodies against C. psittaci occurred in both blood and
BALF about 7 dpi, but only in calves exposed to the challenge
dose of 10
8 ifu. Lower challenge doses did not induce a mea-
surable specific humoral response within two weeks after
inoculation. Whether humoral response to lower challenge doses
requires a longer time or whether challenge doses below 10
8 ifu
are not sufficient to induce humoral response has yet to be
elucidated.
3. Detection of the pathogen: Localization and time-
dependence
Within 14 days after intrabronchial challenge with viable C.
psittaci, different kinds of swabs (nasal, ocular, rectal) collected on a
daily basis were unsuitable to detect the challenge strain by PCR
(data not shown). In lung tissue, however, C. psittaci was detected
by real-time PCR, and increasing copy numbers of the challenge
strain were found in correspondence to increasing challenge doses
until 7 dpi. Furthermore, we were able to recover the challenge
strain in cell culture from lung tissues obtained at necropsy (data
not shown).
The presence of chlamydial inclusions assessed by immuno-
histochemistry was restricted to altered pulmonary tissue while
Figure 5. Numbers of inclusion-forming units (ifu) of C. psittaci in lung tissues. Data are expressed as individual animals. Boxes indicate
control calves euthanized 2–3 dpi after inoculation of UV-inactivated 10
8 ifu. Circles represent calves challenged with viable bacteria of different
doses. Infected calves were sacrificed 3 dpi (red circles), 7 dpi (blue circles) and 14 dpi (open circles). Copy numbers in lung tissue represent the mean
of 4 samples analyzed per lung (two of left caudal lobe and two of right caudal lobe).
doi:10.1371/journal.pone.0030125.g005
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Distribution of any infection or inflammation in the bovine lung is
spatially hampered due to a very high degree of lobulation and
segmentation of pulmonary tissue and the lack of collateral airways
[39,61,62]. Thus, dissemination of infection was impossible via
connective tissue septa between pulmonary segments and could
only happen if infectious particles or droplets would be transported
to other segments by airflow. This however, is less likely for
obligate intracellular pathogens such as chlamydiae. Consequent-
ly, consolidated lobules could be found adjacent to healthy lobules
within the same lung lobe.
4. Exclusion of effects mediated by lipopolysaccharide or
liquid instillation
Inoculation of cell culture medium did not result in any clinical
sign or pulmonary lesion, excluding significant host response to
instillation of 6 ml liquid per lung.
To address the question to what extent chlamydial lipopolysac-
charide (LPS) induced either local effects in the lung or general
clinical signs, we included a second control group that was
inoculated with UV-inactivated C. psittaci at the highest acceptable
dose (10
8 ifu). Compared to controls exposed to cell culture
medium only, calves exposed to inactivated chlamydiae did not
express any significant difference in any parameter assessed in this
study. Consequently, clinical signs of respiratory disease and local
effects of inflammation induced in the lung required viability of the
pathogen. The time course of alterations in calves challenged with
doses 10
6 to 10
8 ifu is consistent with the duration of at least one
chlamydial developmental cycle in the host cells (initial clinical
signs occurred about 48 h after challenge). In calves exposed to
10
9 ifu of C. psittaci, signs of general clinical illness occurred earlier
(less than 24 h after challenge) which might indicate involvement
of toxic products from the pathogen or stronger release of
inflammatory mediators by the host. For challenge doses 10
6 to
10
8 ifu per calf, however, involvement of LPS effects in the
pathogenesis could be excluded.
5. Conclusions
The calf was found to be a suitable mammalian host to establish
and evaluate an in vivo model of experimental respiratory infection
by C. psittaci. Intra-bronchial challenges between 10
6 to 10
9 ifu/
calf resulted in dose-dependent pulmonary and systemic host
reactions ranging clinically from mild to severe. For further
studies, only doses between 10
6 and 10
8 ifu per animal are
recommended, depending on the clinical outcome to be achieved.
While 10
6 ifu of strain DC 15 per animal will lead to a mild or
even subclinical infection, 10
8 ifu per animal causes reproducible
clinically manifest disease and predictable humoral response.
This domestic animal model will add valuable information to
the current knowledge about chlamydial infections obtained from
other studies (laboratory animal or cell culture models). It may be
used to address the following questions with relevance for both
human and veterinary medicine:
1. To study pathogenetic details of C. psittaci infection at the tissue
level, i.e. the interplay between intracellular chlamydial
infection and host cell responses.
2. To verify consequences of C. psittaci infection at the organ level,
i.e. pulmonary dysfunctions in the host.
3. To characterize long-term host-pathogen interactions in vivo.
4. To assess the spread and shedding of the organism in order to
understand the dissemination of the pathogen within the host
and transmission routes between animals, as well as from
animals to humans.
5. To evaluate the usefulness and efficacy of prophylactic and
therapeutic options in order to control chlamydioses in
livestock and, perhaps, eliminate chlamydial infections in
human patients.
Materials and Methods
1. Legislation and ethical approval
This study was carried out in strict accordance with European
and National Law for the Care and Use of Animals. The protocol
was approved by the Committee on the Ethics of Animal
Experiments and the Protection of Animals of the State of
Thuringia, Germany (Permit Number: 04-002/07). All experi-
ments were done in a containment of biosafety level 2 under
supervision of the authorized institutional Agent for Animal
Protection. Bronchoscopy to inoculate the pathogen was strictly
performed under general anesthesia. During the entire study,
every effort was made to minimize suffering.
2. Animals
In this prospective and double-controlled study, 24 convention-
ally raised calves (Holstein-Friesian, male) were included. Animals
originated from one farm without any history of Chlamydia-
associated health problems. Before the study, the herd of origin
was regularly checked for the presence of chlamydiae by the
National Reference Laboratory for Psittacosis. Calves were
purchased at the age of 16 to 26 days weighing between 48 and
76 kg (5766; mean 6 SD). After a quarantine period of at least 20
days and confirmation of a clinically healthy status, animals were
included in the study.
Throughout the entire study, animals were reared under
standardized conditions (room climate: 18 to 20uC) and in
accordance with international guidelines for animal welfare.
Nutrition included commercial milk replacers and coarse meal.
Water and hay were supplied ad libitum. None of the given feed
contained antibiotics.
3. Study design
At the age of 45–54 days, 14 calves weighing 70.864.3 kg were
inoculated with C. psittaci whereas another 10 calves (body weight:
71.667.2 kg) served as controls. By bronchoscope, four challenge
groups received four different infection doses of live C. psittaci
containing the following amounts of inclusion-forming units (ifu) in
6 mL stabilizing medium SPGA (containing saccharose, phos-
phatile substances, glucose and bovine albumin; [63]: 10
6 (n=4),
10
7 (n=4), 10
8 (n=4), and 10
9 (n=2) ifu per animal, respectively.
Controls received either 6 mL containing 10
8 ifu of inactivated
strain DC 15 (n=6) or cell culture medium colored by ink solution
(5 mL per animal; dilution: 1:5).
Animals exposed to 10
6–10
8 ifu of were euthanized and
necropsied 3, 7 or 14 days post inoculation (dpi), while the two
calves exposed to 10
9 ifu were sacrificed 3 dpi. Controls were
euthanized 2 and 3 dpi. Broncho-alveolar lavage was performed,
and lungs were examined and sampled to assess lesions and
presence of C. psittaci.
Before inoculation until necropsy, each calf underwent daily
clinical examination. In addition, blood samples were collected
daily to monitor humoral immune response. Thus, venous blood
was collected from the jugular vein before morning feeding using
9.0 mL plastic syringes (S-Monovette, Sarstedt AG & CoKG,
Respiratory C. psittaci Infection Model
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and stored at 220uC until analyzed.
4. Preparation of bacteria used for inoculation
4.1. Live chlamydiae. Strain DC 15 was isolated at
FRIEDRICH-LOEFFLER-INSTITUT (Jena, Germany) from an aborted
calf fetus in 2002. The isolate was classified as C. psittaci genotype
A-VS1 by DNA microarray testing and ompA gene sequencing
[64]. Chlamydiae were propagated in buffalo green monkey
kidney (BGM) cell culture using standard procedures [65]. Frozen
stocks of strain DC15 were diluted to the required titer in
stabilizing SPGA medium and used as antigen in the present trial.
4.2. Inactivated chlamydiae. Six-well cell culture plates
were filled with 7-mL portions of stabilizing medium containing
10
8 ifu of C. psittaci DC15. Inactivation was achieved by 4.5-h
exposure on a UV Transilluminator plate (UVP Inc. CA, Upland,
CA) and simultaneous irradiation from a UV lamp installed above
the vessel. While 6 mL were preserved as a single-animal dose to
be inoculated, the remains of about 1 mL were left for subsequent
examination of viability of these preparations. Cell culture
passages using immunofluorescence confirmed the inability of
treated chlamydial bodies to re-enter a developmental cycle.
5. Intrabronchial administration
For intrabronchial challenge, the non-fed calf was anesthetized
with xylazin (0.2 mg/kg bodyweight, Rompun 2%, Bayer Vital
GmbH, Leverkusen, Germany) and ketamine (1.760.3 mg/kg
bodyweight, Ursotamin, Serumwerk Bernburg AG, Bernburg,
Germany); both injected intravenously at time intervals of
approximately 3 min.
For inoculation, a flexible video endoscope of 140 cm working
length and outer diameter of 9 mm was used (Veterinary Video
Endoscope PV-SG 22–140, KARL STORZ GmbH & Co.KG,
Tuttlingen, Germany). The endoscope was inserted through a
metal tubular speculum (diameter: 3.5 cm, length: 35 cm) placed
into the calf’s mouth. Defined doses of the freshly prepared C.
psittaci-suspension or cell culture medium, respectively, were
administered at eight defined locations in the lung (Fig. S2) using
a Teflon tube (inner diameter 1 mm, outer diameter 2 mm,
175 cm length, dead space: 1.4 mL) that was inserted through the
working channel (diameter 2.2 mm) of the endoscope.
6. Clinical Scoring
Clinical observations were recorded twice daily and included
feed intake, rectal temperature, respiratory rate, and the presence
or absence of clinical signs of diarrhea or respiratory disease, such
as cough or nasal discharge. In addition, the appearance of oral
mucosa, conjunctivae, skin, hair and dyspnea were assessed daily,
and the heart rate was counted. Extremities, umbilicus and Lnn.
mandibulares were palpated and inducement of cough was tested (by
a short compression of the larynx). Results were summarized using
a 49-point clinical score (Table S1) consisting of sub-scores for
general condition (max. 8 points), respiratory system (max.
17 points), cardiovascular system (max. 13 points) and other
organ systems (max. 11 points).
7. Necropsy and tissue samples
At the end of the study, all animals were euthanized. Under
conditions of deep anesthesia (pentobarbital-sodium, 7706123
mg/10 kg bodyweight, intravenously, Release, WdT eG, Garbsen,
Germany), the trachea was exposed and large clamps were placed
distal to the larynx to prevent contamination of the airways
by blood or gastric contents. Subsequently, the animals were
sacrificed by exsanguination. The lung was removed, macroscopic
lesions recorded and samples collected from each lung lobe. Sites
with macroscopic lesions were preferentially sampled. Aliquots of
each sample were used for histological and immunhistological
examination and detection of C. psittaci by PCR. Then a complete
necropsy was performed.
8. Collection of broncho-alveolar lavage fluid and BALF
analyses
Broncho-alveolar lavage fluid (BALF) was obtained from freshly
exenterated lungs immediately after exsanguination. At three
different locations (Lobus caudalis dexter, Lobus medius, Lobus caudalis
sinister) three subsequent washes using 20 mL of ice-cold cell buffer
(140 mM NaCl; 2.8 mM KCL; 10 mM Na2HPO4612H2O) for
each instillation (in total 180 mL; 60 mL per lung lobe) were
installed using glass syringes and a catheter inserted through the
trachea. BALF obtained by aspiration was immediately placed on
ice. The BALF recovery was 5566% (mean 6 SD) and did not
differ between groups. Cells and supernatant of BALF were
separated by centrifugation (3006g; 20 min).
BALF cytology — Absolute number of leukocytes in BALF was
determined by cell counting using traditional ‘NEUBAUER cham-
bers’. To quantify leukocyte populations, 400 mL of native BALF
were placed on glass slides. The cellular sediments were fixed with
100% methanol for 10 min and subsequently stored at 220uC.
For microscopic examination, the cell sediments were stained
according to PAPPENHEIM (HemaDiff, bioanalytic GmbH, Um-
kirch/Freiburg, Germany), and the percentages of leukocyte
populations (lymphocytes, macrophages, unsegmented and poly-
morphonuclear neutrophil granulocytes) were determined by
counting a total of 100 cells. The absolute cell numbers of the
leukocyte subsets in BALF were calculated based on the absolute
number of leukocytes and the percentages of leukocyte popula-
tions.
Total protein — Concentrations of total protein were measured
in BALF supernatant using commercially available modified
Lowry Protein Assay Kit (Pierce, Rockford IL, USA). Each
sample was analyzed in duplicate.
Eicosanoids — Liquid Chromathography – Tandem Mass
Spectrometry (LC-MS-MS) was used to analyze concentrations of
TXB2, PGE2, 15-HETE, and 12-HETE in BALF supernatant.
Lipid mediators and the deuterated standards were purchased
from Cayman Chemical (Ann Arbor, USA). Solvents and reagents
(water, methanol, acetonitrile, formic acid and ammonium
acetate) were LC-MS grade from Fisher Scientific (Loughborough,
United Kingdom). After adding internal standards, the samples
were filtrated and directly analyzed using an Agilent 1200 HPLC
system coupled with an Agilent 6460 Triplequad mass spectrom-
eter with electrospray ionisation. HPLC conditions were as
follows: Zorbax Stable Bond 3.5 mm, 2.16150 mm column,
injection volume 20 mL, flow rate 0.4 mL/min, elution gradient
from 10% (v/v) acetonitrile to 90% in 10 min, held for another
10 min. Analysis of lipid mediators was performed with Multiple
Reaction Monitoring in negative mode. Results were calculated
using the Agilent Mass Hunter Software.
9. Gross pathology, histopathology,
immunohistochemistry
Distribution, extent and quality of macroscopic pulmonary
lesions were recorded. Tissues collected at necropsy were fixed in
3.5% neutral buffered formalin for 24 h and embedded in
paraffin. Lesions were evaluated in hematoxylin- and eosin-stained
paraffin sections. Chlamydiae were labeled in paraffin sections by
Respiratory C. psittaci Infection Model
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antibody ACI-P500 (Progen, Heidelberg, Germany) as primary
antibody and peroxidase-labeled sheep anti-mouse IgG (NA 931,
GE Healthcare Europe GmbH, Freiburg, Germany) as secondary
antibody. Sections were pre-digested with 0.05% proteinase K
(Merck, Darmstadt, Germany) for antigen retrieval.
10. Detection and quantification of chlamydiae using
real-time PCR
Samples of lung tissue (2 of left caudal lobe, 2 of right caudal
lobe), lung lymph nodes, and BALF-cells were subjected to DNA
extraction using the High Pure PCR Template Preparation Kit
(Roche Diagnostics, Mannheim, Germany) following the instruc-
tions of the manufacturer. One ml of the final eluate was used as
template in real-time PCR testing for the family Chlamydiaceae [66]
and the species of C. psittaci [67].
11. Immunoblotting
Immunoblotting was applied to both sera and BALF to detect
specific antibodies. Lysates of partially purified elementary bodies
of C. psittaci strain DC15 were separated by sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) under reducing
conditions using a standard protocol. BGM cell lysates were
included as controls. Prior to electrophoresis, the protein content
had been determined using the Bradford reagent (Sigma,
Hamburg, Germany), so that equal amounts of protein, i.e. 5 mg
per lane, could be run from each sample. Semi-dry electroblotting
was used to transfer the separated bands onto polyvinylidene
difluoride membranes (PVDF, Amersham Biosciences, NJ, USA).
Subsequently, membranes were blocked with 5% (weight/volume
percent; w/v) skimmed dried milk (Roth, Karlsruhe, Germany) in
TBS-T (10 mM Tris-HCl, 0.15 M NaCl, 0.1% Tween-20,
pH 7.4) for 1 h and probed overnight with serum or BALF
supernatant (both 1:50 dilution in TBS-T). Thereafter, incubation
of Protein G conjugated to horseradish peroxidase (HRP
Calbiochem, Nottingham, UK) was generally performed in 1%
(w/v) bovine serum albumine (Serva, Heidelberg, Germany)
in TBS-T. The blots were stained by adding the HRP sub-
strate chloronaphthol (Sigma, Hamburg, Germany) and photo-
graphed using a G:Box imager and GeneSnap software (Syngene,
Cambridge, UK).
12. Exclusion of co-infections
The herd of origin was known to be free of bovine herpes virus 1
(BHV-1) and bovine virus diarrhoea/mucosal disease virus
(BVDV). Routine microbiological screening revealed that all
animals were negative for Salmonella infections (fecal swabs) and
relevant enteric parasites (fecal smearing). To verify relevant
respiratory co-pathogens, the presence of Mycoplasma, Pasteurella or
Mannheimia spp. was evaluated in nasal swabs taken immediately
before challenge and before necropsy as well as in lung tissue
samples obtained during necropsy. Neither Mannheimia haemolytica
nor Mycoplasma bovis was detected in any sample. Pasteurella
multocida and Mycoplasma bovirhinis was detected at least once in a
nasal swab from 4 of 24 calves (17%) or 8 of 24 calves (33%),
respectively, but never in any lung tissue sample. By serology,
systemic infection with Mycoplasma bovis could be excluded (ELISA
Kit for Mycoplasma bovis, Bio-X-Diagnostics, Jemelle, Belgium).
Serology was also used to check for viral co-pathogens i.e. bovine
respiratory syncytial virus (BRSV), parainfluenza 3 virus (PI-3),
adenovirus type 3, BHV-1 and BVDV (Bio-X respiratory penta
ELISA Kit, Bio-X-Diagnostics,). Only maternal antibodies (with
titers decreasing in the course of the study) were seen against
BRSV (24/24), PI-3 (24/24), and adenovirus type 3 (23/24). In
addition to serology, ear biopsies were examined for the presence
of BVDV by immunohistochemistry [68]. All biopsies were
negative for BVDV antigen indicating that none of the calves
was immunocompromised by persistent BVDV infection.
During the quarantine period, all 24 calves included were
checked serologically for antibodies against chlamydiae (ELISA
test; IDEXX GmbH, Ludwigsburg, Germany). While 23/24 were
serologically negative prior to inoculation, one calf (later
challenged with inactivated chlamydiae) revealed an unexpected
positive test result.
13. Statistical analysis
Data with normal distribution are presented as mean and
standard deviation (SD) while data with non-normal or unknown
distribution are given as median and range (minimum-maximum).
Box and Whisker Plots represent lower and upper quartile values
(box) with median and mean (+). Whiskers extend from each end
of the box to the most extreme values within 1.5 interquartile
ranges. Outliers are data beyond the ends of the whiskers.
Regression analyses according to the best fitting model were
performed to calculate regression lines for the development of total
clinical scores over time per group.
For multiple sample comparison of normally distributed data,
multiple range test (parametric test) was used to compare means.
Kruskal-Wallis test (non-parametric test) was applied to multiple
samples with non-normal distribution to compare medians. To
compare the medians of two groups, Mann-Whitney-Wilcoxon W
test was used. In the latter, the lowest achievable probability level
was 93% due to small sample sizes (n) between n=2 and n=6 per
group. Thus, P-values below P#0.07 were accepted as statistically
significant. For all tests, P-levels are given with the results.
Supporting Information
Figure S1 Dose titration and time course of the humoral
immune response to C. psittaci infection in calves.
Whole-cell proteins of C. psittaci DC15 were separated by SDS-
PAGE. Development of the specific antibody response at three
different infectious doses in serum (A) and BALF supernatants (B)
were analyzed by immunoblotting (no BALF samples from 14 dpi
available). Molecular mass markers (kD) are indicated on the right.
(TIF)
Figure S2 Scheme of intra-bronchial inoculation.
(TIF)
Table S1 Clinical Scoring.
(DOC)
Acknowledgments
The authors are very grateful to Annelie Langenberg, Sylke Stahlberg, Ines
Lemser, and all colleagues of the technical staff of the animal house for
their excellent assistance while performing the in vivo phase of this study. In
depth training in bronchoscopy, supervised by Prof. Sonja Franz (Vienna,
Austria) prior to the study, has been very much appreciated. We thank
Sabine Scharf, Christine Grajetzki and Simone Bettermann for excellent
technical assistance in preparation of the inocula, PCR and related
techniques. Furthermore, we wish to express our gratitude to Kerstin
Heidrich, Sabine Lied, Monika Godat, Kathrin Schlehahn and Franziska
Aschenbrenner for skilful technical assistance in the ex vivo phase, and
Wolfram Maginot for excellent photographic support. Help in microbio-
logical testing given by Dr. Ulrich Methner and Silke Keiling, Dr. Martin
Heller and Susann Bahrmann, Dr. Mandy Elschner, Dr. Astrid Rassbach
and Katja Fischer is gratefully acknowledged. Last but not least, authors
are thankful to Sabine Lenk and Heike Friedrich for assistance in
Respiratory C. psittaci Infection Model
PLoS ONE | www.plosone.org 10 January 2012 | Volume 7 | Issue 1 | e30125formatting the manuscript and to Prof. David L. Hahn (Wisconsin, USA)
for finally editing the English. Part of the data were presented at the 12
th
International Symposium on Human Chlamydial Infections, Hof/Salzburg
(Austria) June 20–25, 2010 and the 1
st European Meeting on Animal
Chlamydioses (EMAC), Murcia (Spain) June 14–16, 2009.
Author Contributions
Conceived and designed the experiments: PR ELT AB KS. Performed the
experiments: PR CO ELT AB AV JL MR AR ES KS. Analyzed the data:
PR CO ELT AB AV JL AR KS. Contributed reagents/materials/analysis
tools: PR CO ELT AB AV JL MR AR ES KS. Wrote the paper: PR CO
ELT AB AR ES KS.
References
1. Vanrompay D, Ducatelle R, Haesebrouck F (1995) Chlamydia psittaci infections: a
review with emphasis on avian chlamydiosis. Vet Microbiol 45: 93–119.
2. Raso Tde F, Godoy SN, Milanelo L, de Souza CA, Matuschima ER, et al.
(2004) An outbreak of chlamydiosis in captive blue-fronted Amazon parrots
(Amazona aestiva) in Brazil. J Zoo Wildl Med 35: 94–96.
3. Laroucau K, de Barbeyrac B, Vorimore F, Clerc M, Bertin C, et al. (2009)
Chlamydial infections in duck farms associated with human cases of psittacosis in
France. Vet Microbiol 135: 82–89.
4. Harkinezhad T, Geens T, Vanrompay D (2009) Chlamydophila psittaci infections
in birds: a review with emphasis on zoonotic consequences. Vet Microbiol 135:
68–77.
5. Gaede W, Reckling K-F, Dresenkamp B, Kenklies S, Schubert E, et al. (2008)
Chlamydophila psittaci infections in humans during an outbreak of psittacosis from
poultry in Germany. Zoonoses & Public Health 55: 184–188.
6. Harkinezhad T, Verminnen K, De Buyzere M, Rietzschel E, Bekaert S, et al.
(2009) Prevalence of Chlamydophila psittaci infections in a human population in
contact with domestic and companion birds. J Med Microbiol 58: 1207–1212.
7. Rohde G, Straube E, Essig A, Reinhold P, Sachse K (2010) Chlamydial
zoonoses. Dtsch A ¨rztebl Int 107: 174–180.
8. Kauffold J, Melzer F, Berndt A, Hoffmann G, Hotzel H, et al. (2006)
Chlamydiae in oviducts and uteri of repeat breeder pigs. Theriogenology 66:
1816–1823.
9. Kauffold J, Melzer F, Henning K, Schulze K, Leiding C, et al. (2006) Prevalence
of chlamydiae in boars and semen used for artificial insemination. Therioge-
nology 65: 1750–1788.
10. Theegarten D, Sachse K, Mentrup B, Fey K, Hotzel H, et al. (2008)
Chlamydophila spp. infection in horses with recurrent airway obstruction:
similarities to human chronic obstructive disease. Resp Res 9: 14.
11. Sprague LD, Schubert E, Hotzel H, Scharf S, Sachse K (2009) The detection of
Chlamydophila psittaci genotype C infection in dogs. Vet J 181: 274–279.
12. Lenzko H, Moog U, Henning K, Lederbach R, Diller R, et al. (2011) High
frequency of chlamydial co-infections in clinically healthy sheep flocks. BMC Vet
Res 7: 29.
13. Reinhold P, Sachse K, Kaltenboeck B (2011) Chlamydiaceae in cattle –
Commensals, trigger organisms, or pathogens? Vet J 189: 257–267.
14. Bazala E, Renda J (1992) Latent Chlamydia infections as the cause of health
disorders in swine, cattle and sheep breeders in Czechoslovakia. Berl Mu ¨nch
Tiera ¨rztl Wochenschr 105: 145–149.
15. Crosse BA (1990) Psittacosis: a clinical review. J Infect 21: 251–259.
16. Haas LE, Tjan DH, Schouten MA, van Zanten AR (2006) Severe pneumonia
from psittacosis in a bird-keeper. Ned Tijdschr Geneeskd 150: 117–121. Dutch.
17. Pandeli V, Ernest D (2006) A case of fulminant psittacosis. Crit Care Resusc 8:
40–42.
18. Otter A, Twomey DF, Rowe NS, Tipp JW, McElligott WS, et al. (2003)
Suspected chlamydial keratoconjunctivitis in British cattle. Vet Rec 152:
787–788.
19. Twomey DF, Griffiths PC, Hignett BC, Martin TP (2003) Suspected chlamydial
polyarthritis in a calf in the UK. Vet Rec 152: 340.
20. Twomey DF, Griffiths PC, Horigan MW, Hignett BC, Martin TP (2006) An
investigation into the role of Chlamydophila spp. in bovine upper respiratory tract
disease. Vet J 171: 574–576.
21. Jaeger J, Liebler-Tenorio E, Kirschvink N, Sachse K, Reinhold P (2007) A
clinically silent respiratory infection with Chlamydophila spp. in calves is associated
with airway obstruction and pulmonary inflammation. Vet Res 38: 711–728.
22. Jee J, Degraves FJ, Kim T, Kaltenboeck B (2004) High prevalence of natural
Chlamydophila species infection in calves. J Clin Microbiol 42: 5664–5672.
23. Reinhold P, Jaeger J, Liebler-Tenorio E, Berndt A, Bachmann R, et al. (2008a)
Impact of latent infections with Chlamydophila species in young cattle. Vet J 175:
202–211.
24. Coers J, Starnbach MN, Howard JC (2009) Modeling Infectious Disease in
Mice: Co-Adaptation and the Role of Host-Specific IFNc Responses. PLoS
Pathog 5(5): e1000333. doi:10.1371/journal.ppat.1000333.
25. Bovine Genome Sequencing and Analysis Consortium, Elsik CG, Tellam RL,
Worley KC, Gibbs RA, et al. (2009) The genome sequence of taurine cattle: a
window to ruminant biology and evolution. Science 324(5926): 522–528.
26. Tellam RL, Lemay DG, Van Tassell CP, Lewin HA, Worley KC, et al. (2009)
Unlocking the bovine genome. BMC Genomics 10: 193.
27. Graphodatsky AS, Trifonov VA, Stanyon R (2011) The genome diversity and
karyotype evolution of mammals. Mol Cytogenet 4(1): 22. [Epub ahead of print].
28. Haley PJ (2003) Species differences in the structure and function of the immune
system. Toxicol 188: 49–71.
29. Pastoret PP, Griebel P, Bazin H, Govaerts A, eds. Handbook of Vertebrate
Immunology. London: Academic Press. 673 p.
30. Hein WR, Griebel PJ (2003) A road less travelled: large animal models in
immunological research. Nat Rev Immunol 3: 79–84.
31. Mestas J, Hughes CC (2004) Of mice and not men: Differences between mouse
and human immunology. J Immunol 172: 2731–2738.
32. Farrar JD, Smith JD, Murphy TL, Leung S, Stark GR, et al. (2000) Selective loss
of type I interferon-induced STAT4 activation caused by a minisatellite insertion
in mouse Stat2. Nature Immunol 1: 65–69.
33. Persson CG (2002) Con: mice are not a good model of human airway disease.
Am J Respir Crit Care Med 166: 6–7.
34. Pabst R (2008) Are Animal Models of Asthma Useful? In: Kay AB, Kaplan AP,
Bousquet J, Holt PG, eds. Allergy and Allergic Diseases. Chichester: Blackwell
Publishing. pp 1214–1222.
35. Coleman RA (2003) Of mouse and man - what is the value of the mouse in
predicting gene expression in humans? Drug Discovery Today 8: 233–235.
36. Kips JC, Anderson GP, Fredberg JJ, Herz U, Inman MD, et al. (2003) Murine
models of asthma. Eur Respir J 22: 374–382.
37. Coraux C, Hajj R, Lesimple P, Puchelle E (2005) In vivo models of human
airway epithelium repair and regeneration. Eur Respir Rev 14: 131–136.
38. Zosky GR, Sly PD (2007) Animal models of asthma. Clin Exp Allergy 37:
973–988.
39. Kirschvink N, Reinhold P (2008) Use of alternative animals as asthma models.
Current Drug Targets 8: 470–484.
40. Rogers CS, Stoltz DA, Meyerholz DK, Ostedgaard LS, Rokhlina T, et al. (2008)
Disruption of the CFTR Gene Produces a Model of Cystic Fibrosis in Newborn
Pigs. Science 321(5897): 1837–1841.
41. Van Rhijn I, Godfroi J, Michel A, Rutten V (2008) Bovine tuberculosis as a
model for human tuberculosis: advantages over small animal models. Microbes
and Infection 10: 711–715.
42. Elferink RO, Beuers U (2009) Are pigs more human than mice? J Hepatology
50: 838–841.
43. Martinez-Olondris P, Rigol M, Torres A (2010) What lessons have been learnt
from animal models of MRSA in the lung? Eur Respir J 35: 198–201.
44. Ireland JJ, Roberts RM, Palmer GH, Bauman DE, Bazer FW (2008) A comment
on domestic animals as dual-purpose models that benefit agricultural and
biomedical research. J Anim Sci 86: 2797–2805.
45. Reynolds LP, Ireland JJ, Caton JS, Bauman DE, Davis TA (2009) Commentary
on Domestic Animals in Agriculture and Biomedical Research: An Endangered
Enterprise. J Nutrition 139: 427–428.
46. Lanzas C, Ayscue P, Ivanek R, Gro ¨hn YT (2010) Model or meal? Farm animal
populations as models for infectious diseases of humans. Nat Rev Microbiol 8:
139–148.
47. McMartin DA, Hunter AR, Harris JW (1979) Experimental pneumonia in red
deer (Cervus elaphus L) produced by an ovine chlamydia. Vet Rec 105:
574–576.
48. Harris JW, Hunter AR, McMartin DA (1984) Experimental chlamydial
pneumonia in pigs. Comp Immunol Microbiol Infect Dis 7: 19–26.
49. Kielstein P, Stellmacher H, Horsch F, Martin J (1983) Chlamydia infection of
swine. 1. Experimental Chlamydia pneumonia of swine. Arch Exp Veterinarmed
37: 569–586. German.
50. Martin J, Kielstein P, Stellmacher H, Horsch F (1983) Chlamydia infections in
swine. 2. Pathologic-histological peculiarities of experimental Chlamydia pneu-
monia in swine. Arch Exp Veterinarmed 37: 939–949. German.
51. Mu ¨ller G, Wehr J, Finsterbusch L (1988) The transformation of peripheral
lymphocytes of calves in immunization and infection with Chlamydia. Arch Exp
Veterinarmed 42: 52–58. German.
52. Everett KDE, Bush RM, Andersen AA (1999) Amended description of the order
Chlamydiales, proposal of Parachlamydiaceae fam. nov. and Simkaniaceae fam. nov.,
each containing one monotypic genus, revised taxonomy of the family
Chlamydiaceae, including a new genus and five new species, and standards for
the identification of organisms. Int J System Bacteriol 49: 415–440.
53. Kuo C-C, Stephens RS (2011) Family I. Chlamydiaceae. In: Krieg NR, et al., eds.
Bergey’s Manual of Systematic Bacteriology. Vol. 4. New York, Dordrecht,
Heidelberg, London: Springer. pp 845–862.
54. Reinhold P, Kirschvink N, Theegarten D, Berndt A (2008b) An experimentally
induced Chlamydia suis infection in pigs results in severe lung function disorders
and pulmonary inflammation. Vet Res 39: 35. doi 10.1051/vetres:2008012.
55. Del Rio L, Buendia AJ, Sanchez J, Garces B, Caro MR, et al., eds. Chlamydophila
abortus (Chlamydia psittaci serotype 1) clearance is associated with the early
recruitment of neutrophils and CD8(+)T cells in a mouse model. J Comp Pathol
123: 171–181.
56. Rupp J, Berger M, Reiling N, Gieffers J, Lindschau C, et al. (2004) Cox-2
inhibition abrogates Chlamydia pneumoniae-induced PGE2 and MMP-1 expression.
Biochem Biophys Res Commun 320: 738–744.
Respiratory C. psittaci Infection Model
PLoS ONE | www.plosone.org 11 January 2012 | Volume 7 | Issue 1 | e3012557. Fukuda EY, Lad SP, Mikolon DP, Iacobelli-Martinez M, Li E (2005) Activation
of lipid metabolism contributes to interleukin-8 production during Chlamydia
trachomatis infection of cervical epithelial cells. Infect Immun 73: 4017–4024.
58. Liu W, Dubinett S, Patterson SL, Kelly KA (2006) COX-2 inhibition affects
growth rate of Chlamydia muridarum within epithelial cells. Microbes Infect 8:
478–86.
59. Liu W, Kelly KA (2008) Prostaglandin E2 modulates dendritic cell function
during chlamydial genital infection. Immunol 123: 290–303.
60. Krausse-Opatz B, Schmidt C, Fendrich U, Bialowons A, Kaever V, er al., eds.
Production of prostaglandin E2 in monocytes stimulated in vitro by Chlamydia
trachomatis, Chlamydophila pneumoniae,a n dMycoplasma fermentans. Microb Pathog 37:
155–161.
61. McLaughlin RF, Tyler WS, Canada RO (1961) A study of the subgross
pulmonary anatomy in various mammals. Am J Anat 108: 149–165.
62. Mitzner W (1991) Collateral ventilation. In: Crystal RG, West JB, et al., eds.
The Lung. Scientific Foundations. New York: Raven Press Ltd. pp 1053–1063.
63. Bovarnick MR, Miller JC, Snyder JC (1950) The influence of certain salts,
amino acids, sugars, and proteins on the stability of rickettsiae. J Bact 59:
509–522.
64. Sachse K, Laroucau K, Vorimore F, Magnino S, Feige J, et al. (2009) DNA
microarray-based genotyping of Chlamydophila psittaci strains from cell culture and
clinical samples. Vet Microbiol 135: 22–30.
65. Goellner S, Schubert E, Liebler-Tenorio E, Hotzel H, Saluz H, et al. (2006)
Transcriptional response patterns of Chlamydophila psittaci in different in vitro
models of persistent infection. Infect Immun 47: 4801–4808.
66. Ehricht R, Slickers P, Goellner S, Hotzel H, Sachse K (2006) Optimized DNA
microarray assay allows detection and genotyping of single PCR-amplifiable
target copies. Mol Cell Probes 20: 60–63.
67. Pantchev A, Sting R, Bauerfeind R, Tyczka J, Sachse K (2009) New real-time
PCR tests for species-specific detection of Chlamydophila psittaci and Chlamydophila
abortus from tissue samples. Vet J 181: 145–150.
68. Cay B, Chappuis G, Coulibaly C, Dinter Z, Edwards S, et al. (1989)
Comparative analysis of monoclonal antibodies against pestiviruses: report of
an international workshop. Vet Microbiol 20: 123–129.
Respiratory C. psittaci Infection Model
PLoS ONE | www.plosone.org 12 January 2012 | Volume 7 | Issue 1 | e30125